ASCO 2023 | Hypofractionated PBT incorporating 18F-DOPA-PET/MRI for elderly patients with glioblastoma

Sujay A. Vora, MD, Mayo Clinic, Phoenix, AZ, provides an overview of a Phase II (NCT03778294) trial investigating short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma. The study enrolled 43 patients, and the primary endpoint was met, with a median progression-free survival (PFS) and overall survival (OS) of 6.5 and 12.9 months, respectively. Patients with MGMT methylation had longer PFS and OS at 11.9 and 29.8 months respectively. Treatment-related adverse events were generally manageable, with no grade 4/5 events reported. Additionally, patient-reported quality of life was improved compared to historical controls. The trial suggests that this treatment approach offers improved OS and quality of life for elderly glioblastoma patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.